🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Diskus

Found 0 matching trials

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study compared the 14-day bronchodilator efficacy of indacaterol with ...

Status

Completed

Location

Novartis Investigator Site

Start Date

2010-03

Trial ID

NCT01089127

Treatments Being Tested

Indacaterol Salmeterol 50 μg Placebo to indacaterol Placebo to salmeterol

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

PHASE4

This trial is a randomized, double-blind, parallel-group, multicenter study...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-04-30

Trial ID

NCT01110200

Treatments Being Tested

ADVAIR DISKUS 250/50 mg BID SEREVENT 50 mcg BID

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

PHASE1

Bioequivalence study between two inhaler products of fixed dose combination...

Status

Completed

Location

BECRO Clinical Facility

Start Date

2020-09-22

Trial ID

NCT04564456

Treatments Being Tested

Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent ADVAIR DISKUS® 500/50

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

PHASE4

The purpose of this study is to evaluate the site and mechanisms responsibl...

Status

Recruiting

Location

Arthur F Gelb Medical Corporation

Start Date

2007-10

Trial ID

NCT01225913

Treatments Being Tested

fluticasone/salmeterol in all asthmatics budesonide/formoterol or fluticasone/salmeterol in all asthmatics

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD

This is a randomized, multi-center, active-controlled, repeated measures de...

Status

Completed

Location

3) Fondazione S. Maugeri - IRCCS - Dipartimento di Pneumologia Riabilitativa

Start Date

2016-04

Trial ID

NCT02757209

Treatments Being Tested

Spiromax (budesonide/formoterol)Turbohaler (budesonide/formoterol)Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

This randomized, cross over study aims to find out the benefits of deliveri...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-09-20

Trial ID

NCT03227445

Treatments Being Tested

ELLIPTA placebo DPI DISKUS placebo DPI HandiHaler placebo DPI Inhaler preference questionnaires

Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The primary objective of this trial was to establish non-inferiority of lun...

Status

Completed

Location

Multiple Locations

Start Date

2005-09

Trial ID

NCT02238106

Treatments Being Tested

Salmeterol medium dose Salmeterol low dose Salmeterol high dose Serevent® Diskus®Placebo HandiHaler®Placebo Diskus®

A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

PHASE1

Bioequivalence study between two inhaler products of ffluticasone propionat...

Status

Unknown

Location

BECRO Clinical Facility

Start Date

2022-05-11

Trial ID

NCT05397834

Treatments Being Tested

Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals FLOVENT DISKUS

The Effect of Salmeterol on Eosinophil (EOS) Function

This study is designed to test the hypothesis that salmeterol use, and not ...

Status

Completed

Location

University of Wisconsin

Start Date

2003-11

Trial ID

NCT00214019

Treatments Being Tested

salmeterol Fluticasone Placebo

Previous Next